

TENNESSEE GENERAL ASSEMBLY
FISCAL REVIEW COMMITTEE



FISCAL NOTE

HB 746 - SB 709

February 24, 2017

SUMMARY OF BILL: Requires the Commissioner of the Department of Mental Health and Substance Abuse Services (DMHSAS), in collaboration with the Commissioner of the Department of Health (DOH), to develop recommended nonresidential treatment guidelines for the use of buprenorphine that can be used by prescribers in this state as a guide for caring for patients by January 1, 2018. Requires the Commissioner to review the nonresidential buprenorphine treatment guidelines by September 30 of each year beginning in 2019, and to post them on the DMHSAS and the DOH websites. Requires the Commissioner of DMHSAS to submit the treatment guidelines to each health-related board that licenses any practitioner authorized by the state to prescribe buprenorphine-containing products for the treatment of an opioid use disorder. Requires the health-related boards to review the guidelines, determine how they should be used by the licensees, and notify all of its licensees through routine bulletins or newsletters of the existence of the nonresidential buprenorphine guidelines and standards.

ESTIMATED FISCAL IMPACT:

NOT SIGNIFICANT

Assumptions:

- Based on information provided by DMHSAS, any fiscal impact associated with developing, reviewing, and posting guidelines will be minimal and can be absorbed within existing resources without an increased appropriation or reduced reversion.
- Based on information provided by the DOH, health-related boards can review the guidelines and notify licensees during normal operations at regularly-scheduled board meetings; therefore, any fiscal impact on health-related boards is estimated to be not significant.

CERTIFICATION:

The information contained herein is true and correct to the best of my knowledge.

A handwritten signature in blue ink that reads "Krista M. Lee".

Krista M. Lee, Executive Director

/jem

HB 746 - SB 709

